论文部分内容阅读
我们自1994年3月～1996年3月,作者用CVP方案联合治疗非小细胞肺癌32例.现报道如下:一、病例选择32例中,男性25例,女性7例,年龄47～68岁,中位年龄60岁.全部为不能手术的中晚期肺癌,经Χ线胸片,胸部CT片及病理确诊.腺癌15例,鳞癌17例,Ⅲa期13例,Ⅲb期15例,Ⅳ期4例.二、方法CTX800mg～1000mg/次,溶于0.9%生理盐水40ml,静注第1天,VDS5mg加入5%GS500ml静滴第1天,DDP50mg加入5%GS NS500ml静滴第2～3天(配合水化).化疗时常规用止吐治疗,DDP当天配合地塞米松5mg静推化疗前.21天为1周期,2～3周期为一疗程,本组病例用药2周期者24例,3周期者8例.疗前进行血尿常规,肝肾功能,胸部Χ线照片,腹部B超,心电图,部分病人加胸部CT,疗程前和化疗结束重复上述检查.三、疗效及毒性评价标准按世界卫生组织(WHO)制定的分级标准,完全缓解(CR),部分缓解(PR),无变化(NC)和进展(PD),CR + PR为有效.四、结果32例中,腺癌15例,鳞癌17例.全组CR3例(9.4%),PR16例(50%),NC13例(40.6%).CR+PR19例,总有效率为59.4%.五、毒副反应Hb降低9例(28.1%),WBC降低14例,(43.8%),Pt降低7例(21.9%),恶心呕吐10例(31.3%),脱发4例
We from March 1994 to March 1996, the author used CVP regimen in the treatment of 32 cases of non-small cell lung cancer. Now reported as follows: First, the case selection of 32 cases, 25 males and 7 females, aged 47 to 68 years old The median age was 60 years old. All patients were inoperable with advanced lung cancer. The chest radiographs, chest CT scans, and pathology confirmed the diagnosis. There were 15 adenocarcinomas, 17 squamous cell carcinomas, 13 stage III a, and 15 stage III b, IV. Period 4 cases. Second, the method CTX800mg ~ 1000mg/times, dissolved in 0.9% saline 40ml, intravenous injection on the first day, VDS5mg added 5% GS500ml intravenous infusion on the first day, DDP50mg added 5% GS NS500ml intravenous infusions 2 ~ 3 Days (with hydration). Antiemetic treatment is routinely used in chemotherapy. DDP is combined with dexamethasone 5mg before intravenous chemotherapy. There are 1 cycle for 21 days, 2 to 3 cycles for one course of treatment, and 24 cycles for 2 cycles in this group of patients. , 3 cycles of 8 cases. Routine hematuria before and after treatment, liver and kidney function, chest squatting photos, abdominal ultrasound, ECG, some patients plus chest CT, before and after the end of chemotherapy repeat the above examination. Third, efficacy and toxicity evaluation criteria According to the grading standards set by the World Health Organization (WHO), complete remission (CR), partial remission (PR), no change (NC) and progression (PD), and CR + PR are effective. IV. Outcome of 32 cases, adenocarcinoma 15 There were 17 cases of squamous cell carcinoma, CR3 cases (9.4%), PR16 cases (50%), NC13 cases (40.6%), CR+PR19 cases, the total effective rate was 59.4%. 5, Hb reduction of toxic side effects was 9 cases. (28.1%), WBC decreased in 14 cases (43.8%), Pt decreased in 7 cases (21.9%), nausea and vomiting in 10 cases (31.3%), and hair loss in 4 cases.